lorglumide has been researched along with Precancerous Conditions in 2 studies
lorglumide: RN given refers to (+-)-isomer
lorglumide : A racemate comprising equal amounts of (R)- and (S)-lorglumide.
N(2)-(3,4-dichlorobenzoyl)-N,N-dipentyl-alpha-glutamine : A dicarboxylic acid monoamide obtained by formal condensation of the alpha-carboxy group of N-(3,4-dichlorobenzoyl)glutamic acid with the amino group of dipentylamine.
Precancerous Conditions: Pathological conditions that tend eventually to become malignant.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (50.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Watanapa, P | 1 |
| Flaks, B | 1 |
| Oztas, H | 1 |
| Deprez, PH | 1 |
| Calam, J | 1 |
| Williamson, RC | 1 |
| Douglas, BR | 1 |
| Woutersen, RA | 1 |
| Jansen, JB | 1 |
| de Jong, AJ | 1 |
| Rovati, LC | 1 |
| Lamers, CB | 1 |
2 other studies available for lorglumide and Precancerous Conditions
| Article | Year |
|---|---|
Inhibitory effect of a cholecystokinin antagonist on pancreatic carcinogenesis after pancreatobiliary diversion.
Topics: Animals; Azaserine; Biliopancreatic Diversion; Body Weight; Cholecystokinin; Cocarcinogenesis; Male; | 1993 |
Modulation by CR-1409 (lorglumide), a cholecystokinin receptor antagonist, of trypsin inhibitor-enhanced growth of azaserine-induced putative preneoplastic lesions in rat pancreas.
Topics: Animals; Azaserine; Cholecystokinin; Esters; Gabexate; Glutamine; Guanidines; Male; Pancreatic Neopl | 1989 |